Evolution of estimated glomerular filtration rate in HIV/HCV-coinfected patients who received direct-acting antivirals : A multicenter retrospective study
Copyright © 2023. Published by Elsevier B.V..
BACKGROUND: The short-term impact of sofosbuvir (SOF)-based direct-acting antivirals (DAAs) combined with antiretroviral therapy (ART) on renal function in patients with HIV/HCV-coinfection remains controversial.
METHODS: This multicenter, retrospective study aimed to sequentially record the estimated glomerular filtration rate (eGFR) at baseline, end of therapy (EOT), 12 weeks off-treatment (SVR12), and at time points after SVR12 (post-SVR12) and to identify the factors associated with an eGFR decline to <60 ml/min/1.73 m2 in HIV/HCV-coinfected patients receiving DAAs. The evolution of mean eGFRs between different ART and DAAs combinations among patients of different HIV transmission routes were compared using a generalized linear mixed effects model. The periods between baseline and EOT, between EOT and post-SVR12, and between baseline and post-SVR12 were defined as the on-treatment, post-treatment, and all-course periods, respectively. Acute kidney disease (AKD) was defined as a decline of eGFR to <60 ml/min/1.73 m2.
RESULT: A total of 445 patients with baseline eGFRs >60 ml/min/1.73 m2 were included. We found that eGFRs declined during the on-treatment period in the tenofovir-containing ART and SOF-based DAA groups. There were no differences in the slope coefficient during the on-treatment and post-treatment periods among all risk groups except for people who inject drug. Increasing age and plasma HIV RNA >20 copies/ml before DAA treatment were factors independently associated with AKD during the on-treatment period while increasing age was independently associated with AKD during the all-course period.
CONCLUSION: Only increasing age was an independent factor associated with AKD among HIV/HCV-coinfected patients during and after DAA treatments.
| Errataetall: |
ErratumIn: J Microbiol Immunol Infect. 2023 Oct 12;:. - PMID 37838594 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:56 |
|---|---|
| Enthalten in: |
Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi - 56(2023), 4 vom: 01. Aug., Seite 718-728 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tsai, Ching-Yen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute kidney disease |
|---|
| Anmerkungen: |
Date Completed 14.08.2023 Date Revised 14.10.2023 published: Print-Electronic ErratumIn: J Microbiol Immunol Infect. 2023 Oct 12;:. - PMID 37838594 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jmii.2023.03.009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355500000 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355500000 | ||
| 003 | DE-627 | ||
| 005 | 20231226064454.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jmii.2023.03.009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1184.xml |
| 035 | |a (DE-627)NLM355500000 | ||
| 035 | |a (NLM)37045634 | ||
| 035 | |a (PII)S1684-1182(23)00077-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tsai, Ching-Yen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evolution of estimated glomerular filtration rate in HIV/HCV-coinfected patients who received direct-acting antivirals |b A multicenter retrospective study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.08.2023 | ||
| 500 | |a Date Revised 14.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: J Microbiol Immunol Infect. 2023 Oct 12;:. - PMID 37838594 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier B.V. | ||
| 520 | |a BACKGROUND: The short-term impact of sofosbuvir (SOF)-based direct-acting antivirals (DAAs) combined with antiretroviral therapy (ART) on renal function in patients with HIV/HCV-coinfection remains controversial | ||
| 520 | |a METHODS: This multicenter, retrospective study aimed to sequentially record the estimated glomerular filtration rate (eGFR) at baseline, end of therapy (EOT), 12 weeks off-treatment (SVR12), and at time points after SVR12 (post-SVR12) and to identify the factors associated with an eGFR decline to <60 ml/min/1.73 m2 in HIV/HCV-coinfected patients receiving DAAs. The evolution of mean eGFRs between different ART and DAAs combinations among patients of different HIV transmission routes were compared using a generalized linear mixed effects model. The periods between baseline and EOT, between EOT and post-SVR12, and between baseline and post-SVR12 were defined as the on-treatment, post-treatment, and all-course periods, respectively. Acute kidney disease (AKD) was defined as a decline of eGFR to <60 ml/min/1.73 m2 | ||
| 520 | |a RESULT: A total of 445 patients with baseline eGFRs >60 ml/min/1.73 m2 were included. We found that eGFRs declined during the on-treatment period in the tenofovir-containing ART and SOF-based DAA groups. There were no differences in the slope coefficient during the on-treatment and post-treatment periods among all risk groups except for people who inject drug. Increasing age and plasma HIV RNA >20 copies/ml before DAA treatment were factors independently associated with AKD during the on-treatment period while increasing age was independently associated with AKD during the all-course period | ||
| 520 | |a CONCLUSION: Only increasing age was an independent factor associated with AKD among HIV/HCV-coinfected patients during and after DAA treatments | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acute kidney disease | |
| 650 | 4 | |a Ageing | |
| 650 | 4 | |a Renal function | |
| 650 | 4 | |a Sofosbuvir | |
| 650 | 4 | |a Tenofovir | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Sofosbuvir |2 NLM | |
| 650 | 7 | |a WJ6CA3ZU8B |2 NLM | |
| 700 | 1 | |a Chen, Guan-Jhou |e verfasserin |4 aut | |
| 700 | 1 | |a Tsai, Chin-Shiang |e verfasserin |4 aut | |
| 700 | 1 | |a Liou, Bo-Huang |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Chia-Jui |e verfasserin |4 aut | |
| 700 | 1 | |a Tsai, Hung-Chin |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Chi-Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Sung-Hsi |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Kuan-Yin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Ning-Chi |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Tun-Chieh |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Chen-Hsiang |e verfasserin |4 aut | |
| 700 | 1 | |a Hung, Chien-Ching |e verfasserin |4 aut | |
| 700 | 0 | |a Taiwan HIV Study Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi |d 1998 |g 56(2023), 4 vom: 01. Aug., Seite 718-728 |w (DE-627)NLM104271183 |x 1995-9133 |7 nnns |
| 773 | 1 | 8 | |g volume:56 |g year:2023 |g number:4 |g day:01 |g month:08 |g pages:718-728 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jmii.2023.03.009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 56 |j 2023 |e 4 |b 01 |c 08 |h 718-728 | ||